It would further be interesting to evaluate the predictive potential of these identified markers with continuing clinical follow-up and together with other established PD progression markers like serum neurofilament light chain5 and dopamine transporter imaging in a longitudinal analysis. This evidence concerns the gene SLC6A3 and Parkinson disease.